Idenix Pharmaceuticals Inc (IDIX) financial statements (2022 and earlier)

Company profile

Business Address 320 BENT STREET
CAMBRIDGE, MA 02141
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments122,006230,826
Cash and cash equivalents122,006230,826
Restricted cash and investments1,4022,103
Receivables1,4091,195
Prepaid expense and other current assets3,668
Other current assets4,935
Total current assets:129,752237,792
Noncurrent Assets
Property, plant and equipment2,7823,274
Long-term investments and receivables5,0826,210
Due from related parties5,0826,210
Other noncurrent assets3,395
Prepaid expense and other noncurrent assets3,589
Total noncurrent assets:11,25913,073
TOTAL ASSETS:141,011250,865
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities19,97218,010
Accounts payable7,7815,771
Accrued liabilities9,3039,293
Employee-related liabilities2,8882,946
Other liabilities392154
Other undisclosed current liabilities(2,174)(2,232)
Total current liabilities:18,19015,932
Noncurrent Liabilities
Liabilities, other than long-term debt13,55011,785
Deferred revenue and credits4,2724,272
Other liabilities9,2787,513
Other undisclosed noncurrent liabilities3,2743,988
Total noncurrent liabilities:16,82415,773
Total liabilities:35,01431,705
Stockholders' equity
Stockholders' equity attributable to parent105,997219,160
Common stock134134
Additional paid in capital935,406926,671
Accumulated other comprehensive income859470
Accumulated deficit(830,402)(708,115)
Total stockholders' equity:105,997219,160
TOTAL LIABILITIES AND EQUITY:141,011250,865

Income statement (P&L) ($ in thousands)

12/31/2013
12/31/2012
Revenues46969,663
Cost of revenue(715)(2,654)
Gross profit:(246)67,009
Operating expenses(125,191)(105,490)
Other undisclosed operating income1,7173,100
Operating loss:(123,720)(35,381)
Nonoperating income1,3502,892
Loss from continuing operations before income taxes:(122,370)(32,489)
Income tax benefit8389
Net loss available to common stockholders, diluted:(122,287)(32,400)

Comprehensive Income ($ in thousands)

12/31/2013
12/31/2012
Net loss:(122,287)(32,400)
Comprehensive loss:(122,287)(32,400)
Other undisclosed comprehensive income, net of tax, attributable to parent389105
Comprehensive loss, net of tax, attributable to parent:(121,898)(32,295)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: